Australia
Razor Labs Launches DataMind AI™ 5.0, Advancing the Next Generation of AI-Powered Predictive Maintenance for Mining
Major platform release expands predictive maintenance beyond fault detection, helping mining companies turn AI insights into faster maintenance decisions and improved asset reliability SYDNEY, July 28, 2026 /PRNewswire/ -- Razor Labs (TASE: RZR), a global leader in AI-powered predictive maintena...
2026-07-28 14:00
1834
Sharon AI to Announce Second Quarter 2026 Results
NEW YORK, July 27, 2026 /PRNewswire/ -- Sharon AI Holdings Inc. (NASDAQ: SHAZ) and its subsidiaries ("Sharon AI"), a leading Australian Neocloud, will release its second quarter 2026 financial results after the market closes on Thursday, August 6, 2026, followed by a conference call and webcast t...
2026-07-27 19:10
1240
Sharon AI Appoints Melissa Anastasiou as Chief Legal Officer
NEW YORK, July 23, 2026 /PRNewswire/ -- Sharon AI Holdings Inc. (NASDAQ: SHAZ) and its subsidiaries ("Sharon AI" or "the Company"), a leading Australian Neocloud, today announced the appointment of Melissa Anastasiou as Chief Legal Officer (CLO). This appointment further strengthens Sharon ...
2026-07-23 19:00
1782
HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
* 250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far * Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027 * Completion of rec...
2026-07-17 11:48
6431
New research reveals loyalty crisis as only 15% of consumers say brand marketing feels relevant - Dotdigital launches AI-powered loyalty platform to help marketers fight back
LONDON, July 16, 2026 /PRNewswire/ -- New global research of 4,000 consumers finds loyalty programmes now rank among the biggest drivers of repeat purchases, while personalisation remains a major blind spot for brands. Consumers are becoming increasingly selective about the brands they stay loya...
2026-07-16 19:25
3731
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeut...
2026-06-25 22:51
3870
Marketplacer Joins Snowflake's MCD Program to Accelerate AI-Powered Autonomous Commerce
Expanded collaboration enables enterprise retailers, brands, and operators to unlock real-time marketplace intelligence and automate supply-side operations through the Snowflake AI Data Cloud MELBOURNE, Australia, June 23, 2026 /PRNewswire/ -- Marketplacer, the global marketplace platform enabli...
2026-06-23 14:00
3726
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
* Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia * 500,000-1 million people are estimated to be living with FSGS in the territories[1] * Dimerix eligible to ...
2026-06-16 19:00
3537
BIFOX ENTERS INTO AGREEMENTS TO ACQUIRE THE 550 MILLION TONNE[1] BAYOVAR 9 PHOSPHATE ROCK PROJECT IN PERU POSITIONING BIFOX TO BECOME ONE OF THE LEADING GLOBAL PHOSPHATE ROCK SUPPLIERS
SYDNEY, June 15, 2026 /PRNewswire/ -- Bifox Limited ("Bifox") is pleased to advise it has entered into two agreements with Fossal S.A.A ("Fossal"), to purchase all of the shares of Fosfatos del Pacífico S.A. ("Fospac"). Under the agreements, Bifox has paid US$10 million cash for 16.667% of the ou...
2026-06-16 08:52
5647
![BIFOX ENTERS INTO AGREEMENTS TO ACQUIRE THE 550 MILLION TONNE[1] BAYOVAR 9 PHOSPHATE ROCK PROJECT IN PERU POSITIONING BIFOX TO BECOME ONE OF THE LEADING GLOBAL PHOSPHATE ROCK SUPPLIERS](https://mma.prnasia.com/media2/2996544/image1.jpg?p=medium600)
Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1
MELBOURNE, Australia, June 11, 2026 /PRNewswire/ -- Lateral Pharma today announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. The ...
2026-06-11 16:22
5544
Infomedia Announces Acquisition of Veact in Europe, Expanding Global Automotive Aftersales Ecosystem
SYDNEY and MUNICH, June 9, 2026 /PRNewswire/ -- Infomedia, a global leader in automotive aftersales technology, has completed the acquisition of Veact GmbH, a leading European provider of data activation, predictive service marketing, and aftersales customer management solutions in the automotive...
2026-06-09 16:00
5351
Fibocom Showcases Smart Connectivity Solutions for AIoT at ElectroneX 2026
SYDNEY, June 3, 2026 /PRNewswire/ -- Fibocom showcased its latest AIoT innovations at ElectroneX 2026 in Australia from June 3–4 at booth D36 under the theme "Intelligent Connectivity for a Smarter World." Targeting the ANZ market, Fibocom presented wireless connectivity solutions for smart payme...
2026-06-03 16:52
6117
HEALEY ALS Platform Trial Regimen I expands to 240 participants
Highlights: * Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements * Increase in sample size driven by enrolment rate exceeding original expectations ...
2026-05-27 22:41
7872
World's smallest deployable operational optical ground station proves capability in successful trials
* Data transferred securely and rapidly between space and ground * Compatible with U.S. Space Development Agency standard * UK Space Minister Liz Lloyd welcomed the news * Units for purchase and service contracts available OXFORD, England, May 27, 2026 /PRNewswire/ -- Archangel Lightworks, ...
2026-05-27 15:00
4450
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Planned Enrollment to Increase from 12 to 36 Patients Following Continued
Encouraging Safety and Tolerability Data
SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics
2026-05-26 19:30
5015
Decision Governance to Enhance Accountability and Transparency of Decisions in Enterprises
The decision governance gap was always there. AI agents just made it impossible to ignore. MELBOURNE, Australia, May 19, 2026 /PRNewswire/ -- FlexRule makes the case that accountability, explainability, and decision quality are not AI problems. They are governance problems that enterprises have ...
2026-05-19 13:52
6028
DAVE & BUSTER'S OPENS IN PERTH AS BRAND CONTINUES GLOBAL EXPANSION
Dave & Buster's makes its Australia debut, expanding its Asia-Pacific footprint Key Highlights * First Dave & Buster's location in Australia opens in Perth. * New venue combines dining, sports viewing and competitive social gaming under one roof. * The opening advances Dave & Buster's conti...
2026-05-19 04:01
5385
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
* RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerabilityto date. * Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, Australia...
2026-05-15 22:25
9374
Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients SYDNEY, May 15, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today ...
2026-05-15 19:06
4968
EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder
* US$13.75M financing completed to accelerate clinical pathway and global commercialisation * Establishment of NinaMED Pty Ltd, a new Australian medtech company * NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to NiNA System®, a non‑invasive, at‑home OAB thera...
2026-05-14 13:03
3242
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
MetaOptics and Elsoft partner to scale next-generation semiconductor optics manufacturing equipment
[Picked up by 286 media titles]
2026-07-30 18:15Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
14998
